Experts explore additional toxicities observed with B-cell maturation antigen–targeting bispecifics, such as infections, neurotoxicity, and hematological issues, and discuss how these are managed in practice.

Experts explain the administration of step-up and treatment doses for GPRC5D at your institution, including whether they are given in clinic or in the community, and will discuss how patients are monitored for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome during the step-up phase.

Although excitement surrounds the constantly changing landscape of cancer care, we have much to learn to keep our practices current.

GC012F, a BCMA/CD19–targeted CAR T-cell therapy, safely produced favorable outcomes in patients with newly diagnosed multiple myeloma after induction therapy.

Merck has discontinued the KEYNOTE-867 and KEYNOTE-630 trials evaluating pembrolizumab in non-small cell lung cancer and cutaneous squamous cell carcinoma.

Companion diagnostics have been approved by the FDA for olaparib plus abiraterone in patients with metastatic castration-resistant prostate cancer.

Adjuvant trastuzumab reveals associations with improved disease-free survival in 1-year vs 9-week administration of the drug in patients with ERBB2-positive breast cancer.

The FDA approved Boruzu, a new presentation of bortezomib, for subcutaneous or intravenous administration in patients with multiple myeloma and mantle cell lymphoma.

This retrospective review demonstrates the increased use of active surveillance in patients with small nonfunctional pancreatic neuroendocrine tumors.

Pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia are receiving tisagenlecleucel in earlier lines of therapy.

Oral cannabis extract may be useful as an adjunct for chemotherapy-induced nausea and vomiting, although it may be associated with additional adverse events.

Enzalutamide produces strong indication of improvements in OS, PCS, TTS, and TTR compared with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC).

Michael Lai, ARNP, explained the mechanism of action of PARP inhibitors for the treatment of patients with prostate cancer.

Throughout August, the FDA approved drugs for the treatment of diseases including non-small cell lung cancer, cutaneous T-cell lymphoma, astrocytoma/oligodendroglioma, and endometrial cancer.

Experts address the unique challenges in managing adverse events associated with GPRC5D therapies compared to other cancer treatments, while Samantha will discuss strategies for preparing and educating patients undergoing GPRC5D therapy.

Experts give an overview of safety data from the MonumenTAL-1 study.

Minimal residual disease status was linked to progression-free survival in patients with chronic lymphocytic leukemia in the first-line treatment setting and with time-limited therapy.

Breakthrough therapy designation has been granted by the FDA to GSK5764227 for potential use in some patients with extensive-stage SCLC.

Tumor sizes reduced from treatment with VP-315 in patients with basal cell carcinoma.

A gene assay was predictive of response to extended letrozole therapy, identifying a subset of patients with low-risk breast cancer with improved outcomes.

Compared to sunitinib, nivolumab plus ipilimumab showed increased overall survival and durable response benefits in patients with advanced renal cell carcinoma.

Oncology nurses are instrumental in assessing cancer-related fatigue and educating patients about potential interventions.

New guidelines for basal cell and squamous cell carcinoma provide detailed criteria for diagnosing, staging, IGRST, and follow-up, among others.

Compared with available literature, the rates of medication-related osteonecrosis of the jaw were higher in patients with breast cancer and bone metastases treated with antiresorptive therapy.

Higher corticosteroid peak dose may worse progression-free and overall survival in several tumor types including melanoma, non-small cell lung cancer, and others.